TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases

Published:2024-08 Issue:16 Volume:10 Page:e36532
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Lin Tao,Tang Xusheng,Yang Wanli,Yang Hainan,Zhou Zhaoming,Chen Zhijie,Zeng Yongqin,Hong Weiping,Ye Minting,Cai Linbo,Liu Da,Li Minying,Wen Lei

Publisher

Elsevier BV

Reference24 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;Journal,2018

2. Progress and prospects of early detection in lung cancer;Blandin Knight;Journal,2017

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;Journal,2009

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;Journal,2010

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Journal,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP